Study EV-302: A two-arm, open-label, randomized controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated advanced urothelial carcinoma (aUC) (trial in progress).

被引：12
|
作者：
Van der Heijden, Michiel Simon
Gupta, Shilpa
Galsky, Matt D.
Derleth, Christina Louise
Lee, Sue
Kataria, Ritesh S.
Powles, Thomas
机构：
[1] Netherlands Canc Inst, Amsterdam, Netherlands
[2] Cleveland Clin Fdn, Taussig Canc Inst, Cleveland, OH USA
[3] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY USA
[4] Seagen Inc, Bothell, WA USA
[5] Astellas Pharma Inc, Northbrook, IL USA
[6] Merck & Co Inc, Kenilworth, NJ USA
[7] Queen Mary Univ London, Barts Canc Inst, Canc Res UK Expt Canc Med Ctr, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.TPS589
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS589
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV plus P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).
    Gupta, Shilpa
    Loriot, Yohann
    van der Heijden, Michiel Simon
    Bedke, Jens
    Valderrama, Begona Perez
    Flechon, Aude
    Petrylak, Daniel P.
    De Santis, Maria
    Galsky, Matt D.
    Lee, Jae Lyun
    Swami, Umang
    Sridhar, Srikala S.
    De Giorgi, Ugo
    Wright, Phoebe
    Lu, Yi-Tsung
    Guan, Xuesong
    Dillon, Ryan
    Homet Moreno, Blanca
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 108 - 108
  • [22] Quality of Life, Functioning, and Symptoms in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma From EV-301: A Randomized Phase 3 Trial of Enfortumab Vedotin vs Chemotherapy
    Gurney, Howard
    Mamtani, Ronac
    Rosenberg, Jonathan E.
    Powles, Thomas
    Sonpavde, Guru P.
    Loriot, Yohann
    Duran, Ignacio
    Lee, Jae Lyun
    Matsubara, Nobuaki
    Vulsteke, Christof
    Castellano, Daniel
    Sridhar, Srikala S.
    Pappot, Helle
    Bedke, Jens
    van der Heijden, Michiel
    Wu Chunzhang
    Hepp, Zsolt
    McKay, Caroline
    Petrylak, Daniel P.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 66 - 67
  • [23] EV-201: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy
    Rosenberg, J. E.
    Balar, A.
    O'Donnell, P. H.
    Heath, E. I.
    Hahn, N. M.
    Cavazos, N. M.
    Melhem-Bertrandt, A.
    Petrylak, D. P.
    ANNALS OF ONCOLOGY, 2018, 29
  • [24] EV-201 Study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy.
    Rosenberg, Jonathan E.
    Heath, Elisabeth I.
    O'Donnell, Peter H.
    Hahn, Noah M.
    Balar, Arjun Vasant
    Gartner, Elaina M.
    Melhem-Bertrandt, Amal
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] EV-201 study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy.
    Rosenberg, Jonathan E.
    Heath, Elisabeth I.
    O'Donnell, Peter H.
    Hahn, Noah M.
    Balar, Arjun Vasant
    Gartner, Elaina M.
    Melhem-Bertrandt, Amal
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [26] Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
    Powles, Thomas
    Csoszi, Tibor
    Ozguroglu, Mustafa
    Matsubara, Nobuaki
    Geczi, Lajos
    Cheng, Susanna Y-S
    Fradet, Yves
    Oudard, Stephane
    Vulsteke, Christof
    Barrera, Rafael Morales
    Flechon, Aude
    Gunduz, Seyda
    Loriot, Yohann
    Rodriguez-Vida, Alejo
    Mamtani, Ronac
    Yu, Evan Y.
    Nam, Kijoeng
    Imai, Kentaro
    Moreno, Blanca Homet
    Alva, Ajjai
    LANCET ONCOLOGY, 2021, 22 (07): : 931 - 945
  • [27] Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
    Powles, Thomas
    van der Heijden, Michiel S.
    Castellano, Daniel
    Galsky, Matthew D.
    Loriot, Yohann
    Petrylak, Daniel P.
    Ogawa, Osamu
    Park, Se Noon
    Lee, Jae-Lyun
    De Giorgi, Ugo
    Bogemann, Martin
    Bamias, Aristotelis
    Eigl, Bernhard J.
    Gurney, Howard
    Mukherjee, Som D.
    Fradet, Yves
    Skoneczna, Iwona
    Tsiatas, Marinos
    Novikov, Andrey
    Suarez, Cristina
    Fay, Andre P.
    Duran, Ignacio
    Necchi, Andrea
    Wildsmith, Sophie
    He, Philip
    Angra, Natasha
    Gupta, Ashok K.
    Levin, Wendy
    Bellmunt, Joaquim
    LANCET ONCOLOGY, 2020, 21 (12): : 1574 - 1588
  • [28] Trial in progress: A phase 2, randomized, open-label study of trilaciclib with first-line, platinum-based chemotherapy and avelumab maintenance in untreated patients with locally advanced or metastatic urothelial carcinoma (PRESERVE 3).
    Sonpavde, Guru P.
    Grivas, Petros
    Milowsky, Matthew I.
    Galsky, Matt D.
    Malik, Rajesh K.
    Beelen, Andrew Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [29] Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.
    Rosenberg, Jonathan E.
    Powles, Thomas
    Sonpavde, Guru P.
    Loriot, Yohann
    Duran, Ignacio
    Lee, Jae-Lyun
    Matsubara, Nobuaki
    Vulsteke, Christof
    Castellano, Daniel E.
    Mamtani, Ronac
    Wu, Chunzhang
    Matsangou, Maria
    Campbell, Mary S.
    Petrylak, Daniel P.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] Phase 3 study of disitamab vedotin with pembrolizumab vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001)
    Galsky, Matt D.
    Grande, Enrique
    Necchi, Andrea
    Drakaki, Alexandra
    Loriot, Yohann
    Franco, Sonia
    Ichimaru, Mari
    Zhang, Wei
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345